Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24
Jair Bar(Tel Aviv University), Penelope A. Bradbury(University Health Network), Lesley Seymour(Queen's University), Christina Addison(Ontario Institute for Cancer Research), Keyue Ding(Ontario Institute for Cancer Research), Frances A. Shepherd(University Health Network), Scott A. Laurie(Ottawa Hospital), Glenwood D. Goss(Ontario Institute for Cancer Research), Lei Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Jim Dimitroulakos(Princess Margaret Cancer Centre), Huijun Zhao(Ministry of Education of the People's Republic of China)
Cited by 7
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k